On December 11, 2023, The company's application for listing of Glucosamine Sulfate Sodium Chloride was accepted and registered by the National Medical Products Administration with acceptance number CYHS2360915 and registration number Y20230001033.　

On September 15th, 2023, the company was issued a Drug Manufacturing License, demonstrating that the company has established a comprehensive quality assurance system capable of ensuring production and quality management activities in accordance with the current Good Manufacturing Practice (cGMP) regulations in China. 　

On August 17th to 18th, 2023, ZheJiang Medical Products Administration conducted an on-site inspection of the company's application for a Drug Manufacturing License. The inspection results generally meet the requirements and are approved.　

Glucosamine acts like a "septum" around the joint in the body. The high density of chitosan in gold shells indicates that the "septum" becomes thinner and stiffer in some osteoarthritis patients.　

Glucosamine hydrochloride is extracted from natural chitin, which can promote the synthesis of mucosaccharides in human body, improve the viscosity of joint synovial fluid, improve the metabolism of joint cartilage, and is conducive to the repair of joint cartilage, anti-inflammatory and analgesic effects